Affimed's Achievements in the Second Quarter
Affimed N.V. (Nasdaq: AFMD), a prominent player in clinical-stage immuno-oncology, has made notable strides in its oncology pipeline during the second quarter of 2024. The company has shared insights not only on its financial performance but also on its ongoing clinical studies aimed at transforming cancer treatment.
Key Clinical Highlights
This quarter's standout achievement includes the promising results from the AFM24 combination therapy with atezolizumab for patients suffering from EGFR mutant non-small cell lung cancer (NSCLC). Among the 24 patients treated, the response evaluation revealed 1 complete response (CR), 3 partial responses (PR), and 8 stable diseases (SD). This translates to an objective response rate (ORR) of 23.5% and a disease control rate (DCR) of 70.6%. Notably, this data is based on a median follow-up period of over 7 months, with 8 patients still actively undergoing treatment.
Further Investigations in NSCLC
The trials for the EGFR wild type (EGFRwt) cohort are progressing well, having enrolled a total of 40 patients. Initial safety and efficacy results are expected by the end of 2024, marking a significant milestone in the ongoing battle against NSCLC.
Progress in Hematologic Malignancies
In another development, the Acimtamig (AFM13) combination therapy with AlloNK® (AB-101) has shown great potential in treating relapsed/refractory Hodgkin Lymphoma (HL). The first two cohorts have successfully completed enrollment, achieving an impressive ORR of 83.3%. Out of 12 patients, 6 complete responses (CRs) were observed, underscoring the promise of this combination therapy for patients who have exhausted all available treatment options.
Encouraging Data from AFM28 Study
The initial phase of the AFM28 monotherapy study has shown that half of the 6 patients treated for relapsed/refractory Acute Myeloid Leukemia (r/r AML) experienced either a complete response (CR) or a complete response with incomplete hematological recovery (CRi). Given these encouraging results, an additional 6 patients will be recruited for further assessment, highlighting the optimistic outlook for Affimed's therapies.
Financial Overview and Stability
Affimed's financial position appears strong, with €34.4 million in cash, cash equivalents, and investments reported as of June 30, 2024. The company has successfully reduced its cash used in operations, decreasing from €33.2 million to €16.5 million compared to the same quarter last year. This improvement is largely due to lowered research and development expenses resulting from strategic restructuring.
Long-Term Financial Projections
The projected cash runway extends into the second half of 2025, ensuring the company can continue its essential clinical programs and research initiatives without immediate financial pressures. Additionally, revenue for Q2 2024 was recorded at €0.2 million, primarily from platform licenses, contrasting with the previous year's figures which included collaborations that have since ended.
Looking Ahead
Affimed's ongoing advancements in immuno-oncology are impressive and hold the potential for significant breakthroughs in cancer treatment strategies. With important milestones in its clinical programs on the horizon, including presentations at scientific conferences planned for late 2024 and early 2025, the company is on a promising and productive path in the realm of cancer therapies.
Frequently Asked Questions
What were the key highlights from Affimed's Q2 2024 report?
Affimed reported encouraging response rates for its AFM24 combination therapy, progress in Hodgkin Lymphoma trials, and improvements in cash flow management.
How does AFM24 perform in non-small cell lung cancer?
The AFM24 therapy achieved a 23.5% objective response rate, with significant disease control observed among treated patients.
What financial position does Affimed hold moving forward?
As of June 30, 2024, Affimed boasts a strong cash position of €34.4 million, with a projected cash runway extending into the second half of 2025.
What milestones are anticipated in Affimed's future clinical studies?
Affimed plans to present key data from ongoing trials at scientific conferences in Q4 2024 and H1 2025, showcasing advancements in its studies.
What is the company’s main focus in oncology?
Affimed is dedicated to leveraging the innate immune system through its innovative ICE® therapies, targeting both hematologic and solid tumors.
